ArticleVaccine2011
Bacillus Calmette-Guérin vaccination using a microneedle patch.
Article in Vaccine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 100 citations in OpenAlex.
- An effective vaccine is only the first step: the need to create and sustain demand for TB vaccines.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- Microneedles: An Emerging Vaccine Delivery Tool and a Prospective Solution to the Challenges of SARS-CoV-2 Mass Vaccination.Pharmaceutics · 2023Review
- Protection against tuberculosis achieved by dissolving microneedle patches loaded with liveFrontiers in immunology · 2023Article
- Microneedle Transdermal Drug Delivery Systems for Allergen-Specific Immunotherapy, Skin Disease Treatment, and Vaccine Development.Yonsei medical journal · 2022Review
- Microneedle-Based Vaccine Delivery: Review of an Emerging Technology.AAPS PharmSciTech · 2022Review
- Low-Temperature Multiple Micro-Dispensing on Microneedles for Accurate Transcutaneous Smallpox Vaccination.Vaccines · 2022Article
- Cryomicroneedles for transdermal cell delivery.Nature biomedical engineering · 2021Article
- A Comprehensive Review of Microneedles: Types, Materials, Processes, Characterizations and Applications.Polymers · 2021Review
- Translation of Polymeric Microneedles for Treatment of Human Diseases: Recent Trends, Progress, and Challenges.Pharmaceutics · 2021Review
- Design of Dissolvable Microneedles for Delivery of a Pfs47-Based Malaria Transmission-Blocking Vaccine.ACS biomaterials science & engineering · 2021Article
- Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases.Expert opinion on drug delivery · 2021Review
- Progress in microneedle array patch (MAP) for vaccine delivery.Human vaccines & immunotherapeutics · 2021Article
- The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization.Expert review of vaccines · 2020Review
- Microneedle Coating Methods: A Review with a Perspective.The Journal of pharmacology and experimental therapeutics · 2019Review
- Needle-Free Immunization with Chitosan-Based Systems.International journal of molecular sciences · 2018Review
- Immunotherapeutic effect of BCG-polysaccharide nucleic acid powder on Mycobacterium tuberculosis-infected mice using microneedle patches.Drug delivery · 2017Article
- BCG vaccine powder-laden and dissolvable microneedle arrays for lesion-free vaccination.Journal of controlled release : official journal of the Controlled Release Society · 2017Article
- The success of microneedle-mediated vaccine delivery into skin.Human vaccines & immunotherapeutics · 2016Review
- Microneedle patches for vaccination in developing countries.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Tuberculosis (TB) caused by Mycobacterium tuberculosis continues to be a leading cause of mortality among bacterial diseases, and the bacillus Calmette-Guérin (BCG) is the only licensed vaccine for human use against this disease. TB prevention and control would benefit from an improved method of BCG vaccination that simplifies logistics and eliminates dangers posed by hypodermic needles without compromising immunogenicity. Here, we report the design and engineering of a BCG-coated microneedle vaccine patch for a simple and improved intradermal delivery of the vaccine. The microneedle vaccine patch induced a robust cell-mediated immune response in both the lungs and the spleen of guinea pigs. The response was comparable to the traditional hypodermic needle based intradermal BCG vaccination and was characterized by a strong antigen specific lymphocyte proliferation and IFN-γ levels with high frequencies of CD4(+)IFN-γ(+), CD4(+)TNF-α(+) and CD4(+)IFN-γ(+)TNF-α(+) T cells. The BCG-coated microneedle vaccine patch was highly immunogenic in guinea pigs and supports further exploration of this new technology as a simpler, safer, and compliant vaccination that could facilitate increased coverage, especially in developing countries that lack adequate healthcare infrastructure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.